- 全部删除
- 您的购物车当前为空
CP94, an iron chelator, enhances protoporphyrin IX photobleaching and reduces the viability of A431 squamous epithelial carcinoma cells at a 150 µM concentration with photodynamic therapy (PDT) using protoporphyrin IX precursors such as aminolevulinic acid (ALA), methyl aminolevulinate (MAL), or hexylaminolevulinate (HAL). Additionally, CP94 (2 mg/ml in drinking water) lowers hepatic non-heme and ferritin-bound iron levels while increasing hepatic protoporphyrin levels in mice. It also counteracts ferrocene-induced rises in rat brain iron levels at a dosage of 100 mg/kg.
CP94, an iron chelator, enhances protoporphyrin IX photobleaching and reduces the viability of A431 squamous epithelial carcinoma cells at a 150 µM concentration with photodynamic therapy (PDT) using protoporphyrin IX precursors such as aminolevulinic acid (ALA), methyl aminolevulinate (MAL), or hexylaminolevulinate (HAL). Additionally, CP94 (2 mg/ml in drinking water) lowers hepatic non-heme and ferritin-bound iron levels while increasing hepatic protoporphyrin levels in mice. It also counteracts ferrocene-induced rises in rat brain iron levels at a dosage of 100 mg/kg.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 8-10周 | |
50 mg | 询价 | 8-10周 |
产品描述 | CP94, an iron chelator, enhances protoporphyrin IX photobleaching and reduces the viability of A431 squamous epithelial carcinoma cells at a 150 µM concentration with photodynamic therapy (PDT) using protoporphyrin IX precursors such as aminolevulinic acid (ALA), methyl aminolevulinate (MAL), or hexylaminolevulinate (HAL). Additionally, CP94 (2 mg/ml in drinking water) lowers hepatic non-heme and ferritin-bound iron levels while increasing hepatic protoporphyrin levels in mice. It also counteracts ferrocene-induced rises in rat brain iron levels at a dosage of 100 mg/kg. |
别名 | CGP 46700 |
分子量 | 167.205 |
分子式 | C9H13NO2 |
CAS No. | 115900-75-9 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容